proprietari alphawis survey support robust switch
ultomiri physician see durabl
impli less global switch price
declin see signific opportun re-rat
expect inflect termin multipl higher
 unit state america
unless otherwis note metric base modelwar
consensu data provid thomson reuter estim
ultomiri switch drive inflect termin multipl current valuat
impli less alexion top drug soliri revenu
switch next-gener version ultomiri
durabl switch poor impli termin growth rate
see substanti upsid strong durabl switch
view support ultomiri superior profil less infus per year
major declin breakthrough hemolysi proprietari survey data
suggest patient could switch year one versu year reach
impli current valuat initi alexion data support
robust switch patient alreadi indic desir switch
first month avail togeth factor drive view
re-rat switch ultomiri drive long-term revenu
project beyond impli current
switch key debat investor debat long-term
durabl soliris/ultomiri franchis base strength ip
protect price market share eros biosimilar brand
competit rate durabl convers ultomiri
believ durabl switch ultomiri obviat first two debat
understand investor focu proprietari alphawis survey point
rapid switch physician expect patient switch
month first year physician said proactiv
prescrib ultomiri exposur profil drug
biosimilar soliri avail physician expect switch patient
soliri ultomiri suggest switch ultomiri
durabl patent manag work hard blunt potenti impact
competit extend soliri patent life us
seek busi
compani cover morgan stanley research
result investor awar firm may
conflict interest could affect object
morgan stanley research investor consid
morgan stanley research singl factor make
invest decis
analyst certif import disclosur
refer disclosur section locat end
japan extens europ pend ultomiri carri ip even
debat patent may litig believ current valuat
impli brand biosimilar competit earli thu see
patent upsid downsid driver final price current
valuat impli price downsid versu long-term
pressur impli blend ultomiri price across key indic
valuat discount provid opportun signific re-rat ultomiri
switch rais price target switch convict base
proprietari model believ valuat impli less durabl switch
ultomiri price current soliri price believ robust
switch support survey data drive durabl lt revenu
growth support lt soliris/ultomiri expect
run-rat impli current valuat support upsid
pt underscor view re-rat rapid ultomiri
switch
signific valuat disconnect present opportun
base proprietari model believ current
valuat impli less durabl switch
ultomiri price declin current soliri price
pipelin valu despit program enter
pivot studi termin growth rate
long-term forecast provid upsid given
view ultormiri switch rapid occur
modest blend across indic price discount
durabl long-term forecast well
impli valuat importantli support
upsid pt
three factor support view long-term durabl
switch ultomiri better drug requir infus
everi week versu everi week soliri
conveni issu also signific qualiti
life issu patient mani lose day work everi
two week lower breakthrough hemolysi
ultomiri improv protect devast
event patient survey data support robust
switch see initi alexion data support
patient desir switch us soliri pnh patient
alreadi indic desir switch first month
avail half patient alreadi ultomiri
exhibit mse revenu forecast versu impli valuat
franchis impli valuat
survey data add evid support view conduct alphawis survey
hematologists/oncologist see total pnh patient
current take soliri base manag recent disclosur
us patient take soliri pnh ahu believ survey
repres us pnh patient see three major implic alexion
ultomiri switch
switch expect physician expect patient switch
ultomiri first month avail first year thu
believ insur verif certain logist hurdl may slow rate
would expect vast major us pnh patient switch year
see manag switch target highli achiev
high newli diagnos patient share physician recept prescrib
ultomiri first line treatment awar clinic data
physician expos profil ultomiri report state
proactiv prescrib drug irrespect physician familiar
data would like prescrib ultomiri first line would
prescrib soliri may requir inform make decis
physician survey plan put pnh patient
potenti biosimilar pressur modest versu rate impli current valuat
potenti competit soliris/ultomiri remain murki
investor expect potenti biosimilar earli ask physician
impact biosimilar soliri biosimilar price discount
soliri physician expect patient soliri patient
ultomiri would switch biosimilar importantli physician would expect fight
insur compani keep patient brand soliri due
low awar ultomiri among patient physician
report patient request inform survey physician
present high level profil ultomiri phiii result pnh
state proactiv prescrib drug exhibit
exhibit ultomiri patient interest awar clinic data
exhibit expect treatment ultomiri among total
convers rate patient ultomiri soliri expect within
month post launch total within year exhibit total pnh
patient expect switch soliri ultomiri base physician
need data oncologist plan put pnh
patient ultomiri
exhibit switch ultomiri februari share patient pnh soliri
regard new patient oncologist like prescrib ultomiri first line
treatment like start soliri requir inform
exhibit expect treatment new pnh patient among total
exhibit assum biosimilar eculizumab avail
price discount soliri
physician express interest switch potenti biosimilar biosimilar
eculizumab avail price discount physician expect switch
patient soliri ultomiri biosimilar exhibit
patient soliri survey patient treat less
year year year exhibit pnh
patient soliri receiv mg dose receiv
exhibit durat soliri treatment share patient pnh
soliri
exhibit mainten dose share patient pnh soliri
market price less durabl switch
built proprietari model estim rate biosimilar penetr
ultomiri switch impli current valuat base model believ
investor expect signific biosimilar penetr unswitch soliri patient
modest ultomiri switch signifi price reduct
patient switch ultomiri base survey work believ manag
execut expect drive higher importantli also believ
us share soliri
us biosimilar share soliri
exu share soliri
exu biosimilar share soliri
discount flow
termin valu
ultomiri clinic data strensiq kanuma soliri label expans nmo drive
ultomiri clinic data strensiq kanuma soliri label expans nmo drive
overweight believ
current valuat impli manag
unabl grow busi
overlook share shift potenti
ultomiri even conserv scenario
assum ultomiri achiev solid
profil assum either market share
price pressur year
assum strensiq achiev
meaning sale see modest sale
key revenu driver model
continu ahu pnh sale growth
franchis coupl growth
soliri mg success share shift
ultomiri model nmo sale start
risk achiev price
soliri pnh ahu mg growth could fail
meet expect soliri nmo may
launch strensiq and/or kanuma could fail
meet expect ultomiri could fail
leav soliri unprotect competit
could potenti bad
behavior identifi commerci
deriv pt discount cash flow analysi assum
wacc termin growth rate revenu driver
model pnh sale ahu sale mg sale nmo sale strensiq
sale kanuma sale incorpor cash cost stock
diagnost algorithm drive sustain pnh ahu mg penetr soliri
approv nmo ultomiri succe signific share convers
bull case assum soliri becom standard care pnh ahu nmo
mg pnh sale peak ww ahu sale
peak assum strensiq kanuma continu launch
sale respect
soliri meaning growth pnh ahu gmg ultomiri succe
modest share convers base case assum solid convers ultomiri
long-term durabl complement franchis assum gmg
nmo meaning contribut sale also assum strensiq peak sale
kanuma see soliri longev incorpor
competit price pressur
soliri fail nmo strensiq kanuma achiev minim sale soliri face
signific competit bear case assum soliri fail gain label
expans soliri face signific headwind biosimilar
proprietari competit diversif strensiq kanuma minim
alphawis
